International Stem Cell (ISCO) EBIAT (2016 - 2025)
International Stem Cell (ISCO) has disclosed EBIAT for 16 consecutive years, with $129000.0 as the latest value for Q2 2025.
- On a quarterly basis, EBIAT rose 8.4% to $129000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was -$240000.0, a 64.91% increase, with the full-year FY2024 number at -$213000.0, down 62.6% from a year prior.
- EBIAT was $129000.0 for Q2 2025 at International Stem Cell, up from -$256000.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of $492000.0 in Q2 2023 to a low of -$599000.0 in Q1 2021.
- A 5-year average of -$94222.2 and a median of -$79500.0 in 2023 define the central range for EBIAT.
- Biggest YoY gain for EBIAT was 24700.0% in 2023; the steepest drop was 2091.3% in 2023.
- International Stem Cell's EBIAT stood at -$351000.0 in 2021, then soared by 106.55% to $23000.0 in 2022, then plummeted by 2091.3% to -$458000.0 in 2023, then skyrocketed by 102.62% to $12000.0 in 2024, then skyrocketed by 975.0% to $129000.0 in 2025.
- Per Business Quant, the three most recent readings for ISCO's EBIAT are $129000.0 (Q2 2025), -$256000.0 (Q1 2025), and $12000.0 (Q4 2024).